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It is difficult to give an overall impressio n on the European situation because equipment, regulations and, last but not least, medical practice patterns differ from one country to the other even within the European Union. On the European level, nuclear medicine has been recognized as a full medical specialty since 1989. In many European countries it is not possible to practice medicine in more than one specialty even if fully trained in more than one. In some countries these regulations are changing, and physicians are or will be allowed to have more than one specialist title provided they fulfill the requirements of continuing education in all specialties. According to a survey published in a 1996 position paper by the Nuclear Medicine Section of the Union of European Medical Specialists (UEMS), 1 nuclear medicine studies in cardiology are mostly performed by certified nuclear medicine specialists. For legal reasons, only these specialists are allowed to administer radioactive tracers to patients. In the Scandinavian countries, clinical physiology deals with all kinds of functional studies, including those performed with radioactive tracers. In the other countries, a few nonnuclear medicine physicians (cardiologists, radiologists) perform such studies. In many centers, cardiologists perform or at least are present during stress tests, but only in a small number of countries is their presence mandatory.
Training in nuclear medicine varies from country to country as well. A 1996 syllabus prepared by The European Board of Nuclear Medicine (EBNM) listed the minimal requirements for training as at least 3 years in nuclear medicine and 1 or 2 years in one or more other specialties. This training period is to include clinical activity with bedside training and performance of a minimum of 500 nuclear cardiology studies. The revised form of this syllabus has been published in the European Journal of Nuclear Medicine. 2 All of these requirements, of course, must be considered only as directives that can, but need not, be accepted as the foundation of laws and rules that are set up at the national level.
Since 1993 the proportion of presentations in the cardiovascular domain during the European Annual Meetings of the European Association of Nuclear Medicine (EANM) tends to diminish slightly. There are probably several reasons for this apparent decrease (Table 1) , which should not be interpreted as a decrease of scientific activity in this field'. Other topics that have gained interest (in particular oncology) fill time slots previously available for cardiology papers. The absolute number of presented abstracts remained rather stable except for the number presented at the last meeting, which clashed with the annual meeting of the European Society of Cardiology (ESC). Considering that 90 nuclear medicine papers were selected for presentation there and 110 at the EANM meeting, the scientific interest in this field seems well preserved. Not only quantity but also quality seems to be at good levels: the rejection rate of nuclear medicine and radiology abstracts at the ESC meeting was 26% compared with an overall rejection rate of 48%.
In addition to these two large European meetings, the International Conference of Nuclear Cardiology (ICNC) in early 1997 also drained an important number of presentations that otherwise would have been submitted to the annual meeting.
As for bone scans, which are widely performed but are the subject of only a very limited number of abstracts submitted to the EANM Annual Congress, myocardial perfusion studies are today considered routine and are no longer the subject of widespread methodologic debate even if the final standard of performing such studies still needs to be defined. Due to the importance of myocardial perfusion imaging, nuclear cardiology occupies the second or third position of the number of nuclear medicine studies in most countries despite the contraction of the volume of radionuclide ventriculography, which tends to be replaced by echocardiography. 3 Volume 5, Number 5;538-41 Nuclear cardiology: A European perspective
The scientific interest in myocardial perfusion and viability imaging has shifted from methodology to questions such as standardization, quality control, clinical impact, decision-making, cost-efficacy, and cost-benefit. A recent European cost-benefit study has shown that diagnostic management strategies that include myocardial perfusion imaging in the evaluation of patients with possible coronary artery disease generate significantly fewer costs than strategies that do not include the nuclear medicine test. This difference in cost is not only observed at diagnosis but persists after 2 years of follow-up. 4
In addition to lower costs, strategies including myocardial perfusion imaging have higher diagnostic power at diagnosis and a lower negative coronary angiography rate. These results, which were collected in four western European countries, are an important signal to health authorities, hospital managers, and insurance companies. The discussion on the cost-effectiveness of assessing hibernating myocardium is ongoing. 5
Medical practice and availability of medical resources differ within the European Union already, but the differences are even more important when we also take into consideration the situation in eastern and central Europe. Many of our colleagues in those countries who have had access to modern technology only recently and in a very limited fashion have made a tremendous effort to make these newer techniques available to their colleagues and patients and to promote training of medical and technical staff.
The penetration of myocardial perfusion imaging still shows great variations from one country to the other. The following comments are based on a survey by Iskandrian and Giubbini 6 that compared nuclear cardiology in the United States and Europe. They showed that the number of myocardial perfusion studies per million inhabitants varied greatly even within the European Union, with the high being 8400 in Belgium and the low 264 in Ireland. As expected, the number of myocardial perfusion studies is still much lower (173/million inhabitants) in eastern and central European countries. At first glance, the density of gamma cameras appears to play a role in this difference because Belgium has the highest density in Europe (24/million inhabitants), but Ireland is not at the other extreme for the camera density. There are more cameras in Ireland than in Portugal after normalization for the population, but the number of myocardial perfusion studies per gamma camera is only 58 in Ireland and 285 in Portugal, which is well beyond the European annual average of 183. Table 2 compares the distribution in percentage of scientific presentations in the field of cardiology at the 1997 EANM Congress in Glasgow 7 and of the myocardial perfusion studies performed in Europe. 6 In most countries there is a balance between the scientific and clinical activity in cardiology, with myocardial perfusion imaging representing by far the most important part. It is worth noting that in Greece, Turkey, and eastern and central European countries, scientific participation exceeds the clinical activity by a factor of 2, 4, and 3, respectively. The situation in Belgium is special. In this country we find not only the highest gamma-camera density, but also the greatest imbalance in favor of the clinical activity. This finding does not mean that the scientific activity in this country is poor; in fact, the percentage of presentations is 1.7 times higher than the percentage of the Belgian population in Europe, which indicates a scientific productivity with respect to the number of inhabitants comparable to that of Germany. There are probably several other reasons for this imbalance which might have socioeconomic and cultural roots. The greater availability of camera time, and thus the absence of waiting lists, is certainly not a major argument because the number of studies performed per camera is much higher (350) than in all of the other European countries except France (395). I dare to speculate that the popularity of nuclear cardiology in Belgium results from its development by a certain number of nuclear physicians trained in cardiology whose academic and clinical activity was either preferentially or exclusively devoted to nuclear medicine in cardiology, which favored the clinical impact of the technique.
In my opinion, this shows the importance of cooperation between the two specialties to promote nuclear medicine in cardiology. First, we need to speak a common language. 8 The nuclear physician needs to understand what information the cardiologist needs to manage cases efficiently, and this information must be given in clinical terms. According to the EBNM syllabus interpreted for the field of cardiovascular nuclear medicine, trainees in nuclear medicine should follow a program
